Other treatments have ongoing or concluded CVOTs investigating CV safety1
Victoza® is the only GLP-1 RA recommended by the ADA to lower CVD event rates and mortality in patients with established CVD1,a
ACE=American College of Endocrinology; ADA/EASD=American Diabetes Association/European Association for the Study of Diabetes; CV=cardiovascular; CVD=cardiovascular disease; CVOT=cardiovascular outcomes trial; DPP-4=dipeptidyl peptidase-4; GI=gastrointestinal; GLP-1 RA=glucagon-like peptide-1 receptor agonist; OAD=oral antidiabetic drug; SGLT-2=sodium glucose cotransporter-2; SUs=sulfonylureas; TZDs=thiazolidinediones.
- American Diabetes Association. Standards of medical care in diabetes—2018. Diabetes Care. 2018;40(suppl 1):S1-S159.
- Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2018 executive summary. Endocr Pract. 2018;24(1):91-120.